Optimizing clinical research procedures in public health emergencies.
COVID-19
N-of-1
Public Health Emergency
artificial intelligence
clinical trial
ethics
master protocols
platform studies
randomized trials
umbrella trial
Journal
Medicinal research reviews
ISSN: 1098-1128
Titre abrégé: Med Res Rev
Pays: United States
ID NLM: 8103150
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
10
05
2020
revised:
14
10
2020
accepted:
22
10
2020
pubmed:
12
11
2020
medline:
11
3
2021
entrez:
11
11
2020
Statut:
ppublish
Résumé
Public Health Emergencies of International Concern, such as the coronavirus disease 2019 pandemic, have a devastating impact on an individual and societal level, and there is an urgent need to learn, understand and bridge the therapeutic gap at a time of extreme stress on the patient, health care systems and staff. Well-designed, controlled clinical trials play a crucial role in the discovery of novel diagnostic and management strategies; however, these catastrophic circumstances pose unique challenges in initiating research studies at institutional, national, and international levels, highlighting the importance of a coordinated, collaborative approach. This review discusses key elements necessary to consider for developing clinical trials within a Public Health Emergency setting.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
725-738Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
WHO. Strengthening health security by implementing the International Health Regulations (2005) https://www.who.int/ihr/procedures/pheic/en/. Accessed March 23, 2020.
Remuzzi Andrea, Remuzzi Giuseppe. COVID-19 and Italy: what next? The Lancet. 2020;395:1225-1228. http://doi.org/10.1016/s0140-6736(20)30627-9
Dodd LE, Proschan MA, Neuhaus J, et al. Design of a randomized controlled trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study. J Infect Dis. 2016;213:1906-19013.
Thielman NM, Cunningham CK, Woods C, Petzold E, Sprenz M, Russell J. Ebola clinical trials: five lessons learned and a way forward. Clin Trials. 2016;13:83-86.
Kalincik T, Butzkueven H. Observational data: understanding the real MS world. Multiple sclerosis. 2016;22:1642-1648.
Booth CM. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801-2809.
Wei-jie G, Zheng-yi N, Yu H, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199-1207.
Caraballo C, McCullough M, Fuery MA, et al. COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system. PLoS One. 2020;15:e0238829.
Li Q, Lin J, Chi A, Davies S. Practical considerations of utilizing propensity score methods in clinical development utilizing real-world and historical data. Contemp Clin Trials. 2020;97:106123.
Vellinga A, Cormican M, Hanahoe B, Bennett K, Murphy AW. Opt-out as an acceptable method of obtaining consent in medical research: a short report. BMC Med Res Methodol. 2011;11:40.
Government of Canada. Panel on Research Ethics. TCPS 2 (2018) - Chapter 3: The consent process. https://ethics.gc.ca/eng/tcps2-eptc2_2018_chapter3-chapitre3.html. Accessed March 30, 2020.
Clark AM, Jamieson R, Findlay IN. Registries and informed consent. N Engl J Med. 2004;351:612-614.
World Health Organization. WHO guidelines on ethical issues in public health surveillance. https://apps.who.int/iris/bitstream/handle/10665/255721/9789241512657-eng.pdf?sequence=1. Accessed April 6, 2020.
Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377:62-70.
Lin J, Bunn V. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials. Contemp Clin Trials. 2017;54:48-59.
Parmar MK, Sydes MR, Cafferty FH, et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: multi-arm, multi-stage platform, umbrella and basket protocols. Clin Trials. 2017;14:451-461.
Sudhop T, Brun NC, Riedel C, Rosso A, Broich K, Senderovitz T. Master protocols in clinical trials: a universal Swiss Army knife? Lancet Oncol. 2019;20:e336-e342.
Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015;313:1619-1620.
Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353-2366.
Davey RT, Jr., Dodd L, Proschan MA, et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;375:1448-1456.
Master Protocols: Efficient Clinical Trial Design Strategies To Expedite Development of Oncology Drugs and Biologics. Draft Guidance for Industry https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and. Oct 2018.
Mirza RD, Punja S, Vohra S, Guyatt G. The history and development of N-of-1 trials. J R Soc Med. 2017;110:330-340.
Hekler EB, Klasnja P, Chevance G, Golaszewski NM, Lewis D, Sim I. Why we need a small data paradigm. BMC Med. 2019;17:133.
Davidson Karina W, Cheung Ying Kuen, McGinn Thomas, Wang Y Claire. Expanding the Role of N-of-1 Trials in the Precision Medicine Era: Action Priorities and Practical Considerations. NAM Perspectives. 2018. http://doi.org/10.31478/201812d
Zucker DR, Schmid CH, McIntosh MW, D'Agostino RB, Selker HP, Lau J. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol. 1997;50:401-410.
Punja S, Bukutu C, Shamseer L, et al. N-of-1 trials are a tapestry of heterogeneity. J Clin Epidemiol. 2016;76:47-56.
Huber AM, Tomlinson GA, Koren G, Feldman BM. Amitriptyline to relieve pain in juvenile idiopathic arthritis: a pilot study using Bayesian metaanalysis of multiple N-of-1 clinical trials. J Rheumatol. 2007;34:1125-1132.
Stunnenberg BC, Deinum J, Nijenhuis T, et al. N-of-1 Trials: evidence-based clinical care or medical research that requires IRB approval? A practical flowchart based on an ethical framework. Healthcare (Basel). 2020;8(1):49.
Vohra S, Shamseer L, Sampson M, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. J Clin Epidemiol. 2016;76:9-17.
Porcino AJ, Punja S, Chan AW, et al. Protocol for a systematic review of N-of-1 trial protocol guidelines and protocol reporting guidelines. Syst Rev. 2017;6:132.
Kravitz R, Duan N Design and Implementation of N-of-1 Trials: A User's Guide. Publication No 13(14)-EHC122-EF Rockville, MD: Agency for Healthcare Research and Quality January 2014.
Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20:273-286.
Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (Revised). Guidance for Industry and Food and Drug Administration Staff. June 2020. https://www.fda.gov/media/136290/download. Accessed October 4, 2020.
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic. Guidance for Industry, Investigators, and Institutional Review Boards. Updated on March 21, 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-pandemic. Accessed March 28, 2020.
Angus Derek C. Randomized Clinical Trials of Artificial Intelligence. JAMA. 2020;323(11):1043. http://doi.org/10.1001/jama.2020.1039
Parikh RB, Teeple S, Navathe AS. Addressing bias in artificial intelligence in health care. JAMA. 2019;322:2377.
Emanuel EJ, Wachter RM. Artificial intelligence in health care: will the value match the hype? JAMA. 2019;321:2281-2282.
Nayak VS, Khan MS, Shukla BK, Chaturvedi PR. Artificial intelligence in clinical research. Int J Clin Trials. 2016;3(4):187-193.
Woo M. An AI boost for clinical trials. Nature. 2019;573(7775):S100-S102.
Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci. 2019;40:577-591.
Taylor K, Properzi F, Cruz MJ Intelligent clinical trials. Deloitte. 2020. https://www2.deloitte.com/us/en/insights/industry/life-sciences/artificial-intelligence-in-clinical-trials.html. Accessed April 15, 2020.
Matheny ME, Whicher D, Thadaney, Israni S. Artificial intelligence in health care: a report from the national academy of medicine. JAMA. 2020;323:509-510.
Orlando AW, Rosoff AJ. The new privacy crisis: what's health got to do with it? Am J Med. 2019;132:127-128.
McCradden MD, Baba A, Saha A, et al. Ethical concerns around use of artificial intelligence in health care research from the perspective of patients with meningioma, caregivers and health care providers: a qualitative study. CMAJ Open. 2020;8:E90-E95.
FDA. Good Clinical Practice. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/good-clinical-practice. Accessed March 29, 2020.
Enhancing the Diversity of Clinical Trial Populations - Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). June 2019. https://www.fda.gov/media/127712/download. Accessed October 4, 2020.
WHO training manual. Ethics in epidemics, emergencies and disasters: Research, surveillance and patient care. http://apps.who.int/iris/bitstream/10665/196326/1/9789241549349_eng.pdf?ua=1. Accessed March 29, 2020
Government of Canada. Panel on Research Ethics. TCPS 2 (2018) - Chapter 6: Governance of Research Ethics Review. https://ethics.gc.ca/eng/tcps2-eptc2_2018_chapter6-chapitre6.html#21. Accessed March 29, 2020.
WHO. Ethical standards for research during public health emergencies: Distilling existing guidance to support COVID-19 R&D. https://www.who.int/blueprint/priority-diseases/key-action/liverecovery-save-of-ethical-standards-for-research-during-public-health-emergencies.pdf?ua=1. Accessed April 4th, 2020.
Saxena A, Horby P, Amuasi J, et al. Ethics preparedness: facilitating ethics review during outbreaks-recommendations from an expert panel. BMC Med Ethics. 2019;20:29.
EMA. Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic Version 2 (27/03/2020) https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/guidanceclinicaltrials_covid19_en.pdf. Accessed March 28, 2020.
Government of Canada. Management of clinical trials during the COVID-19 pandemic: Notice to clinical trial sponsors. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/management-clinical-trials-during-covid-19-pandemic.html. Accessed April 4, 2020.
WHO. Piloting the PHEEPR Network (Public Health Emergency Ethics Preparedness and Response) https://wwwwhoint/news-room/detail/26-01-2020-piloting-the-pheepr-network. Accessed March 26, 2020.
Lurie N, Manolio T, Patterson AP, Collins F, Frieden T. Research as a part of public health emergency response. N Engl J Med. 2013;368:1251-1255.
Platform for European Preparedness Against (Re-)emerging Epidemics. https://www.prepare-europe.eu/. Accessed March 21, 2020.
London AJ, Kimmelman J. Against pandemic research exceptionalism. Science. 2020;368:476-477.
Kalil AC Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA. 2020.